Advertisement

Topics

Supplemental NDA for Astellas' Overactive Bladder Treatment Reviewed by FDA

10:56 EDT 13 Sep 2017 | PharmPro

U.S. FDA accepts for review Astellas' supplemental New Drug Application for mirabegron for use in combination with solifenacin succinate 5 mg for the treatment of overactive bladder.
Contributed Author: 
Astellas Pharma Inc.
Topics: 

Original Article: Supplemental NDA for Astellas' Overactive Bladder Treatment Reviewed by FDA

NEXT ARTICLE

More From BioPortfolio on "Supplemental NDA for Astellas' Overactive Bladder Treatment Reviewed by FDA"

Quick Search
Advertisement
 

Relevant Topic

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...